Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivoryon Therapeutics reports promising Phase 2 results from its VIVA-MIND study, highlighting varoglutamstat’s significant improvement in kidney function, despite the study’s discontinuation due to unmet endpoints in Alzheimer’s disease. This supports the potential advancement of varoglutamstat in treating diabetic kidney disease, reinforcing previous findings from the VIVIAD study. The drug continues to show a favorable safety profile, bolstering its prospects in clinical development.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.